Amgen (AMGN) Convertible Debt (2009 - 2010)

Amgen (AMGN) posted quarterly Convertible Debt of $2.2 billion for Q1 2010, down 51.22% quarter-over-quarter from $4.5 billion in Q4 2009.

Amgen (AMGN) Convertible Debt (2009 - 2010) Analysis & Trends

Amgen's Convertible Debt history runs 2 years deep, the most recent figure standing at $2.2 billion for Q1 2010.

In Q1 2010, Convertible Debt changed N/A year-over-year to $2.2 billion; the TTM figure through Mar 2010 stood at $2.2 billion (changed N/A YoY), while the FY2009 annual figure was $4.5 billion, changed N/A from the prior year.
Convertible Debt for Q1 2010 stood at $2.2 billion, down from $4.5 billion in the prior quarter.
The five-year high for Convertible Debt was $4.5 billion in Q4 2009, with the low at $2.2 billion in Q1 2010.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	652.20 Bn	631.44 Bn	17.26 Bn
2	AbbVie	469.51 Bn	462.94 Bn	12.70 Bn
3	Merck	376.81 Bn	369.67 Bn	12.21 Bn
4	Novartis Ag	303.04 Bn	295.35 Bn	11.24 Bn
5	Astrazeneca	257.61 Bn	252.71 Bn	12.86 Bn
6	Amgen	237.37 Bn	223.38 Bn	7.24 Bn
7	Gilead Sciences	181.73 Bn	178.55 Bn	6.22 Bn
8	Pfizer	159.66 Bn	147.96 Bn	10.94 Bn
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn
10	Sanofi	55.07 Bn	47.69 Bn	10.79 Bn

Download Data